Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic bacteria have cytoplasmic (plasma) membranes composed primarily of phospholipids and proteins, with other unique adaptations depending on the type (Gram-negative or Gram-positive)[2][4][5]. In Gram-negative bacteria, this includes a distinctive outer membrane containing lipopolysaccharide (LPS), which is a major virulence determinant and the source of endotoxin[3][4][5]. The bacterial membrane acts as a selective barrier, houses essential metabolic enzymes (e.g., for respiration), and is a functional target for several classes of antibiotics. Disruption of bacterial membranes is a proven therapeutic strategy, but targeting specificity and host toxicity remain challenges[2][3][5]. Targeting membrane structure or function is particularly relevant in combatting antibiotic-resistant pathogens, as membrane composition and permeability often underlie resistance mechanisms[4][5].
Disruption of membrane integrity, Increased membrane permeability, Destabilization of membrane potential or proton motive force
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial membrane (of pathogenic bacteria).